News
![AT&T CEO: Price Increases Bring Value To Customers Through Free Added BenefitsPhoto, wide shot, wide-angle lens, soft focus, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-pKgbwxVSbyTCu0UzPNe8NL8D.png?st=2023-05-04T16%3A02%3A58Z&se=2023-05-04T18%3A02%3A58Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T12%3A13%3A51Z&ske=2023-05-05T12%3A13%3A51Z&sks=b&skv=2021-08-06&sig=%2BhYssNp3W0HiZMxCV64XVELyP8stYUjFhgUVfPrTLyg%3D](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMFlBYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--55e18ad4b9f4c7438f915dcb43544d37a3598a63/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T12-3A13-3A51Z&ske=2023-05-05T12-3A13-3A51Z&sks=b&skv=2021-08-06&sig=-2BhYssNp3W0HiZMxCV64XVELyP8stYUjFhgUVfPrTLyg-3D.png?locale=us)
AT&T CEO: Price Increases Bring Value To Customers Through Free Added Benefits
Following is the unofficial transcript of a CNBC interview with AT&T Inc. (NYSE:T) CEO John Stankey on CNBC’s “Squawk on the Street” (M-F, 9AM-12PM ET) today, Wednesday, September 6 from the GS
![Medigene AG präsentiert auf der 25. H.C. Wainwright Annual Global Investment Conference](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Medigene AG präsentiert auf der 25. H.C. Wainwright Annual Global Investment Conference
Planegg/Martinsried (05.09.2023). Die Medigene AG (Medigene, FWB: MDG1, Prime Standard) ist ein immunonkologisches Plattformunternehmen, das sich auf die Erforschung und Entwicklung von
![Medigene AG to present at the H.C. Wainwright 25th Annual Global Investment Conference](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Medigene AG to present at the H.C. Wainwright 25th Annual Global Investment Conference
Planegg/Martinsried (05.09.2023). Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies
![Investors Push Back On Pharma Lawsuits To Thwart Medicare Negotiated Pricing](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Investors Push Back On Pharma Lawsuits To Thwart Medicare Negotiated Pricing
NEW YORK, NY, THURSDAY, AUGUST 31, 2023 - Today, investors released a statement voicing deep concern about lawsuits brought by pharma companies and trade groups to block the U.S. government’s
![Medigene presents rationale for combining its 3S TCRs with enhancement tools as an approach to improve clinical outcomes](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Medigene presents rationale for combining its 3S TCRs with enhancement tools as an approach to improve clinical outcomes
Planegg/Martinsried (30.08.2023) - Medigene AG (Medigene or the "Company", FSE: MDG1, Prime Standard) is an immuno-oncology platform company focusing on the discovery and development of T
![Medigene zeigt Konzept für Kombination seiner 3S TCRs mit Verbesserungswerkzeugen zur Optimierung klinischer Resultate](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Medigene zeigt Konzept für Kombination seiner 3S TCRs mit Verbesserungswerkzeugen zur Optimierung klinischer Resultate
Planegg/Martinsried (30.08.2023). Die Medigene AG (Medigene oder das "Unternehmen", FWB: MDG1, Prime Standard) ist ein immunonkologisches Plattformunternehmen, das sich auf die Erforschung
![Drug Companies Impacted By Biden Rx Cost Saving Effort Boasted Of $38.7b In Profits In 2022](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Drug Companies Impacted By Biden Rx Cost Saving Effort Boasted Of $38.7b In Profits In 2022
WASHINGTON, DC – The Biden administration has announced the first 10 prescription drugs impacted by the Inflation Reduction Act’s measures giving Medicare the power to negotiate lower prices
![$400 One-Time Tax Rebate From Virginia Now A Viable Option](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
$400 One-Time Tax Rebate From Virginia Now A Viable Option
After months of negotiations, state lawmakers have finally agreed on the state budget, clearing the way for the one-time tax rebate from Virginia. Eligible individuals could get $200, while
![5 High-Yielding S&P Stocks: Is It The Right Time To Buy?: https://www.flatex.at/fileadmin/dateien_flatex/images/logos/logo-claim_flatex-at_positiv_rgb.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeG5oVVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b69713a1a725bfbdb6127b83617e316a5f0244d5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo-claim_flatex-at_positiv_rgb.png?locale=us)
5 High-Yielding S&P Stocks: Is It The Right Time To Buy?
Key Points
- Dividends have historically contributed 32% of the S&P 500's total returns.
- However, high-yield stocks may indicate trouble, with declining stock prices and earnings often
![Medigene AG: Medigene erweitert IP-Rechte für die kostimulatorischen Switch-Proteine auf weitere Zelltypen](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Medigene AG: Medigene erweitert IP-Rechte für die kostimulatorischen Switch-Proteine auf weitere Zelltypen
Planegg/Martinsried (23.08.2023) Die Medigene AG (Medigene oder das "Unternehmen", FWB: MDG1, Prime Standard), ein immunonkologisches Plattformunternehmen, das sich auf die Erforschung und
![Medigene AG präsentiert auf dem 8. CAR-TCR Summit in Boston](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Medigene AG präsentiert auf dem 8. CAR-TCR Summit in Boston
Planegg/Martinsried (22.08.2023) Die Medigene AG (Medigene, FWB: MDG1, Prime Standard), ein immunonkologisches Plattformunternehmen, das sich auf die Erforschung und Entwicklung von
![Medigene AG to present at the 8th CAR-TCR Summit in Boston](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Medigene AG to present at the 8th CAR-TCR Summit in Boston
Planegg/Martinsried (22.08.2023) Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for
![Are High-Yielding AT&T And Verizon Worth Buying As Prices Skid?Photo, wide shot, wide-angle lens, soft focus, Amusement park, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by David Maisel: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-9ykfBOFTwqbOHnaukQ2bUqdm.png?st=2023-05-13T13%3A50%3A52Z&se=2023-05-13T15%3A50%3A52Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-12T20%3A43%3A22Z&ske=2023-05-13T20%3A43%3A22Z&sks=b&skv=2021-08-06&sig=G2Gltvd1Lg2exXRILeKuP5%2BTSWMna0SOjxb75jCyrG0%3D](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN2NMYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9cfbe4455fabc73e7da3ad10e657961b6e37d682/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-12T20-3A43-3A22Z&ske=2023-05-13T20-3A43-3A22Z&sks=b&skv=2021-08-06&sig=G2Gltvd1Lg2exXRILeKuP5-2BTSWMna0SOjxb75jCyrG0-3D.png?locale=us)
Are High-Yielding AT&T And Verizon Worth Buying As Prices Skid?
Key Points
- AT&T and Verizon remain attractive to income investors with dividend yields of nearly 7.8%.
- AT&T’s revenue has been growing slowly, despite 5G customer additions, while Verizon’s
![Preparing For The Return To The Office As A Single Parent? Here Are Ten Practical Tips That Can Help You Adjust](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Preparing For The Return To The Office As A Single Parent? Here Are Ten Practical Tips That Can Help You Adjust
After nearly three years of remote working, countless employers, from startup companies to multinational conglomerates are now requesting employees to return to the office five days a week.
![A Year Later, Industry Still Lobbying Against Inflation Reduction Act’s Success For Average Americanshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=us)
A Year Later, Industry Still Lobbying Against Inflation Reduction Act’s Success For Average Americans
WASHINGTON, DC – One year ago today, the landmark Inflation Reduction Act began making big corporations pay their fair share in taxes while reinvesting in priorities that help grow the middle class
![Medigene AG veröffentlicht Halbjahresbericht 2023 und gibt ein Unternehmensupdate](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Medigene AG veröffentlicht Halbjahresbericht 2023 und gibt ein Unternehmensupdate
Planegg/Martinsried (17.08.2023/08:00 UTC+2)
- Erweiterung der Pipeline um Neoantigene mit mehreren KRAS-Mutationen als erste Zielstrukturen
- Erwerb der exklusiven,
![Medigene nimmt an der H.C. Wainwright Immune Cell Engager Virtual Conference teil](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Medigene nimmt an der H.C. Wainwright Immune Cell Engager Virtual Conference teil
Planegg/Martinsried (16.08.2023). Die Medigene AG (Medigene, FWB: MDG1, Prime Standard), ein Immunonkologie-Unternehmen, das sich auf die Erforschung und Entwicklung von T-Zell-Immuntherapien
![Medigene to participate in the H.C. Wainwright Immune Cell Engager Virtual Conference](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Medigene to participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
Planegg/Martinsried (16.08.2023). Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies
![EnWave unterzeichnet Vereinbarung mit Moleciwl Cyf über Technologieevaluierung und Lizenzoptionen](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
EnWave unterzeichnet Vereinbarung mit Moleciwl Cyf über Technologieevaluierung und Lizenzoptionen
VANCOUVER, British Columbia, 16. August 2023 - EnWave Corporation (TSX-V:ENW | FWB:E4U) („EnWave“ oder das „Unternehmen“) gab heute bekannt, dass das Unternehmen eine Vereinbarung über
![EnWave Signs Technology Evaluation and License Option Agreement with Moleciwl Cyf](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
EnWave Signs Technology Evaluation and License Option Agreement with Moleciwl Cyf
VANCOUVER, British Columbia, Aug. 16, 2023 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") announced today that it has signed a Technology Evaluation and License
![Medigene AG berichtet über das zweite Quartal und veröffentlicht Halbjahresbericht 2023 am 17. August 2023](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Medigene AG berichtet über das zweite Quartal und veröffentlicht Halbjahresbericht 2023 am 17. August 2023
Planegg/Martinsried (10.08.2023) - Die Medigene AG (Medigene oder das "Unternehmen", FWB: MDG1, Prime Standard), ein immunonkologisches Plattformunternehmen, das sich auf die Erforschung und
![Gov. Signs Largest Property Tax Cut In Texas History: How it Benefits You: https://www.valuewalk.com/wp-content/uploads/2023/08/Texas-300x150.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWR2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fcd1d47eed7beed1088340d72e932bf79484cc56/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Texas-300x150.jpeg?locale=us)
Gov. Signs Largest Property Tax Cut In Texas History: How it Benefits You
Texas Gov. Greg Abbott ceremonially signed the $18 billion property tax relief bill into law on Wednesday. The bill, which is the largest property tax cut in Texas history, will bring massive
![Residential Prices, Rents Dip Across Qatar As World Cup Boost Dissipates: https://www.valuewalk.com/wp-content/uploads/2023/08/Rental-Rate-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXhxYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9a8176e7a5718cc499381ff1aace12fa16a2ec0a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Rental-Rate-1.jpg?locale=us)
Residential Prices, Rents Dip Across Qatar As World Cup Boost Dissipates
Residential market declines amid supply surge, office market faces oversupply challenges, retail market competes with increasing pressure, and hotel occupancy falters despite spike in tourist
Therapie von gastrointestinalen Stromatumoren: QIAGEN erhält FDA-Zulassung für Begleitdiagnostikum zu AYVAKIT® (avapritinib) von Blueprint Medicines
therascreen® PDGFRA RGQ PCR-Kit von QIAGEN in USA zugelassen, um Patienten mit inoperablen oder metastasierenden gastrointestinalen Stromatumoren und PDGFRA-D842V-Mutation zu ermitteln, die für eine
![BioNTech veröffentlicht Ergebnisse des zweiten Quartals 2023 und Informationen zur Geschäftsentwicklunghttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=us)
BioNTech veröffentlicht Ergebnisse des zweiten Quartals 2023 und Informationen zur Geschäftsentwicklung
- Wichtige Fortschritte in der Weiterentwicklung der Pipeline durch den Beginn der zulassungsrelevanten Phase-3-Studie mit BNT316/ONC-392 sowie Vorbereitungen für mehrere geplante Studienstarts im